Search
Search Menu

Paul Moser

Paul trained as a pharmacologist in the UK, first in Bristol, then in Bath for his Ph.D., specialising in chronopharmacology. He has spent over 30 years in the pharma industry in both big and medium pharma companies, biotech and also in contract research. After a few …

Read more

Rita Balice-Gordon

Rita Balice-Gordon, Ph.D., is the Global Head, Rare and Neurologic Diseases Research Therapeutic Area at Sanofi, Inc.  She leads groups of scientists based in Boston and Paris working on small molecules, antibodies and gene therapy as modalities for discovering and developing innovative and transformative therapeutics for patients …

Read more

Phil Skolnick

Dr. Skolnick is the Chief Scientific Officer at Opiant Pharmaceuticals, Inc. Prior to joining Opiant, he was the Director, Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse, NIH (2010-2017).  He served as Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, …

Read more

Valentina Vengeliene

Valentina obtained a PhD in pharmacology from Heidelberg University in 2005, based on her research done at the Central Institute of Mental Health in Mannheim, Germany. Following her PhD, she continued as a scientist at the Central Institute of Mental Health, focusing on addiction. In particular, …

Read more

C. Glenn Begley

M.B., B.S., Ph.D., F.R.A.C.P., F.R.C.P.A., F.R.C.Path., F.A.H.M.S. Dr Begley is the inaugural CEO of BioCurate, a joint initiative of Monash and Melbourne Universities and created to provide commercial focus in the early phases of drug development. He served as Chief Scientific Officer at Akriveia Therapeutics, California (2016-2027) …

Read more

Dan Deaver

During my academic career I fostered important research collaborations both within and outside the university related to drug development. These efforts required the generation of robust data packages. In the late 1980s, I worked closely with the Upjohn Company during their development of recombinant bovine somatotropin. …

Read more

Rob Miller

Rob Miller has 17 years of biopharma commercial experience with Lilly, Abbott and AbbVie that provides the PAASP US team with an in-depth understanding of how future PAASP biopharma customers develop risk-adjusted valuations for both internal and external innovation:     •New product commercial development and for over …

Read more

Patricia Kabitzke

I obtained my PhD from the City University of New York in Neuroscience, followed by a Postdoctoral fellowship at the Columbia university in New York. During the latter, I completed two projects: 1.) I investigated the neural mechanisms underlying the innate fear response early in life, …

Read more

Andre Der-Avakian

Andre Der-Avakian is Assistant Professor of Psychiatry at the University of California San Diego (UCSD) and Associate Member of the American College of Neuropsychopharmacology (ACNP). He is Principal Investigator on research projects funded by grants from the National Institute of Mental Health (NIMH) and National Institute …

Read more

Prof. Dr. Malcolm Macleod

Malcolm Macleod, BSc(Hons) MBChB PhD FRCP Ed, is Professor of Neurology and Translational Neuroscience at the University of Edinburgh, head of Neurology at Forth Valley Royal Hospital, and Honorary Principal Research Fellow, Florey Neurosciences Unit, Melbourne, Australia.  Prof. Macleod was a founding co-ordinator of the Collaborative …

Read more

Scroll Up